cas 2799-21-5|| where to buy (R)-3-Pyrrolidinol

Nombre del producto:(R)-3-Pyrrolidinol

IUPAC Name:(3R)-pyrrolidin-3-ol

Unidad de embalaje	Stock disponible	Precio($)
CM116633-25g	in stock	ŌŮ
CM116633-100g	in stock	ƴŤŌ
CM116633-500g	in stock	ƈŤŌ

Sólo para uso en I+D..

Formulario de consulta

Nombre químico

Número CAS

Cantidad*

Especificaciones requeridas*
(% de ensayo, grado de material, etc.)

Nombre de contacto*

Correo electrónico de contacto*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 2799-21-5 regularly via the above email.

Notas adicionales

Verification code*

refresh

: Núm. De CAS :2799-21-5; Fórmula molecular:C4H9NO; Punto de fusión:-; Código de sonrisas:O[C@H]1CNCC1; Densidad:

: Número de catálogo:CM116633; Peso molecular:87.12; Punto de ebullición:224.7°C at 760 mmHg; Nº Mdl:MFCD00145220; Almacenamiento:Keep in dark place, inert atmosphere, store at 2-8°C.

: Pyrrolidines; Pyrrolidine, also known as tetrahydropyrrole, is a saturated five-membered heterocyclic ring, which is miscible with water. Pyrrolidine exists in many alkaloids and drug molecules, such as kappa opioids, antagonists of dopamine D4 receptors, and HIV reverse transcriptase inhibitors.

: Pyrroles; Pyrrole is a five membered heterocyclic compound with the molecular formula of C4H5N. Pyrrole has a ring composed of four carbon atoms and one nitrogen atom. Pyrrole is easy to polymerize in the air. Pyrrole is the parent compound of many important biological substances (such as bile pigment, porphyrin and chlorophyll). Pyrrole scaffolds are widely used in biological and pharmaceutical fields. Pyrrole is a special heterocyclic scaffold, which exists in many natural products, drug molecules and pesticides, and has shown its application in materials science.

: Asciminib; Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile. Scemblix now approved for newly diagnosed and previously treated CML, allowing four times the patients access to potential new standard of care.
Scemblix is an orally available tyrosine kinase inhibitor that works by blocking the BCR-ABL1 fusion protein, a known hallmark of certain leukemias. The drug was first approved for CML three years ago, winning two indications. The first is for the treatment of Philadelphia chromosome-positive, chronic phase CML, for which the drug was given accelerated approval. The second is a full approval for the same patient population, with the additional specification that they carry the T315I mutation.